drugset / Trial / NCT01867294
Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab
Phase 2
Completed
19 enrolled
Academic and Community Cancer Research United
National Cancer Institute (NCI) · collab
RandomizedParallel-groupSingle-blindSupportive care
Summary
This randomized phase II trial studies how well giving spironolactone works in preventing rash in patients with cancer that has spread to other places in the body and are receiving panitumumab and cetuximab. Spironolactone may prevent endothelial growth factor receptor (EGFR) inhibitor-induced skin rash.
Timeline
- Start
- 2012-08-31
- Primary completion
- 2014-05-09
- Completion
- 2014-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Spironolactone | Small molecule | — | Topical |
| Comparator | Doxycycline | Small molecule | — | Oral |
| Comparator | Hydrocortisone | Other / unclassified | — | Topical |